Sign In
Free Newsletter
New Jersey builds on legacy of leadership in life sciences
New Jersey's life sciences industry tops 127,000 workers as a new report highlights biotech growth, manufacturing and innovation.
Opella builds consumer health business after Sanofi split
One year after its Sanofi spinout, Morristown-based Opella is accelerating innovation and expanding its consumer healthcare business.
NJ Assembly advances PBM reform bill to cut drug costs
The New Jersey General Assembly advanced a measure that aims to lower prescription drug costs, increase transparency and regulate PBMs in New Jersey's healthcare system.
Merck wins FDA approval for once-daily HIV pill Idvynso
The clearance for Idvynso, which combines doravirine and islatravir for adults with HIV-1, helps expand treatment options for patients.
NJ life sciences demand steady as vacancy rises: Colliers
A new life sciences market report from Colliers places New Jersey in the top 10 markets nationwide, citing strong workforce, leasing activity and long-term growth outlook.
Shionogi completes $2.5B deal for ALS drug Radicava rights (updated)
Shionogi completed a $2.5 billion deal for the rights to ALS drug Radicava from Jersey City-based Tanabe Pharma Corp.
Novo Nordisk launches Wegovy subscription plan with savings
The new option offers lower monthly pricing for self-pay patients via telehealth platforms, such as Weight Watchers, LifeMD, Hims & Hers and Sesame, to expand access to GLP-1 weigh loss drugs.
Bridgewater pharma recalls 90K bottles of children’s ibuprofen
Strides Pharma recalls nearly 90,000 bottles of children’s ibuprofen after reports of a gel-like mass and black particles, according to the FDA notice.
Novo Nordisk, Hims & Hers settle GLP-1 drug dispute
The settlement between Novo Nordisk and Hims & Hers allows the telehealth platform to sell FDA-approved Wegovy and Ozempic GLP-1 drugs.
Novo Nordisk threatens legal action over Hims Wegovy copy (updated)
Novo Nordisk is threatening the telehealth provider over a $49 compounded copycat therapy, escalating scrutiny of GLP-1 weight-loss drug alternatives.
NJ sues Novartis over alleged generic drug price fixing
New Jersey joins a multistate lawsuit accusing Novartis and Sandoz of price fixing 31 generic drugs, raising costs for consumers, Medicare and Medicaid.
Cambrex to invest $120M to expand U.S. drug production
The East Rutherford-based CDMO will boost capacity at the nation's largest independent API manufacturing site and add jobs in Iowa amid reshoring efforts.
